BioPharma Credit PLC
BPCP.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -8.3% | -26.3% | 109.4% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | -£0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | £0 | £0 | £0 | £0 |
| % Margin | 98.2% | 79.9% | 99% | 96.6% |
| Other Income/Exp. Net | £0 | -£0 | £0 | £0 |
| Pre-Tax Income | £0 | £0 | £0 | £0 |
| Tax Expense | £0 | £0 | £0 | £0 |
| Net Income | £0 | £0 | £0 | £0 |
| % Margin | 98.2% | 79.9% | 99% | 96.6% |
| EPS | 0.1 | 0.083 | 0.13 | 0.062 |
| % Growth | 20.8% | -36.3% | 110.4% | – |
| EPS Diluted | 0.1 | 0.083 | 0.13 | 0.062 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | -£0 | -£0 | -£0 | -£0 |
| EBITDA | £0 | £0 | £0 | £0 |
| % Margin | 98.2% | 0% | 0% | 0% |